Formosa Pharmaceuticals, Inc.

TWSE:6838 Stock Report

Market Cap: NT$5.7b

Formosa Pharmaceuticals Valuation

Is 6838 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6838 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6838's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6838's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6838?

Key metric: As 6838 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6838. This is calculated by dividing 6838's market cap by their current revenue.
What is 6838's PS Ratio?
PS Ratio41.4x
SalesNT$137.46m
Market CapNT$5.68b

Price to Sales Ratio vs Peers

How does 6838's PS Ratio compare to its peers?

The above table shows the PS ratio for 6838 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.3x
6620 Handa Pharmaceuticals
7.9xn/aNT$7.7b
6785 Alar Pharmaceuticals
19.3x-133.2%NT$9.2b
1271 SunWay Biotech
6.2xn/aNT$5.0b
4166 Orient Pharma
7.7xn/aNT$8.3b
6838 Formosa Pharmaceuticals
41.4xn/aNT$5.7b

Price-To-Sales vs Peers: 6838 is expensive based on its Price-To-Sales Ratio (41.4x) compared to the peer average (10.3x).

Price to Sales Ratio vs Industry

How does 6838's PS Ratio compare vs other companies in the TW Pharmaceuticals Industry?

13 CompaniesPrice / SalesEstimated GrowthMarket Cap
3705 YungShin Global Holding
1.8xn/aUS$440.32m
1720 Standard Chemical & Pharmaceutical
1.6xn/aUS$334.85m
4746 Formosa Laboratories
1.8x7.8%US$258.91m
1734 Sinphar PharmaceuticalLtd
1.8xn/aUS$164.44m
6838 41.4xIndustry Avg. 4.6xNo. of Companies13PS0816243240+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6838 is expensive based on its Price-To-Sales Ratio (41.4x) compared to the TW Pharmaceuticals industry average (4.6x).

Price to Sales Ratio vs Fair Ratio

What is 6838's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6838 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio41.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6838's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 18:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Formosa Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution